Page last updated: 2024-10-26

eicosapentaenoic acid ethyl ester and Huntington Disease

eicosapentaenoic acid ethyl ester has been researched along with Huntington Disease in 8 studies

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

ExcerptRelevanceReference
"To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid, improves the motor features of Huntington disease."9.13Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. ( , 2008)
"To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid, improves the motor features of Huntington disease."5.13Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. ( , 2008)
"The Unified Huntington's Disease Rating Scale (UHDRS) was used for assessment."2.71Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. ( Greenamyre, JT; Hayden, MR; Hersch, S; Horrobin, DF; Leavitt, BR; Manku, M; Murck, H; Puri, BK; Rosenblatt, A; Ross, CA; Sword, A; Vaddadi, KS, 2005)
"Cystamine treatment of various genetic models of HD demonstrated protection against neurodegeneration and/or improvement in behavior."1.37Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. ( Leavitt, BR; Sivananthan, SN, 2011)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Morsy, S1
Khalil, SM1
Doheim, MF1
Kamel, MG1
El-Basiony, DSM1
Ahmed Hassan, HI1
Eisa, AA1
Anh Ngoc, CT1
Dang, NP1
Hirayama, K1
Huy, NT1
Ferreira, JJ1
Rosser, A1
Craufurd, D1
Squitieri, F1
Mallard, N1
Landwehrmeyer, B1
Sivananthan, SN1
Leavitt, BR3
Puri, BK2
Hayden, MR2
Ross, CA1
Rosenblatt, A1
Greenamyre, JT1
Hersch, S1
Vaddadi, KS2
Sword, A1
Horrobin, DF2
Manku, M2
Murck, H2
Van Raamsdonk, JM1
Pearson, J1
Rogers, DA1
Lu, G1
Barakauskas, VE1
Barr, AM1
Honer, WG1
Bydder, GM1
Counsell, SJ1
Corridan, BJ1
Richardson, AJ1
Hajnal, JV1
Appel, C1
Mckee, HM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease[NCT00146211]Phase 3300 participants (Actual)Interventional2005-09-30Completed
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881]Phase 3609 participants (Actual)Interventional2008-03-31Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Behavioral Frequency Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day1.39
B - Placebo1.43

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day4.29
B - Placebo5.06

Change in Functional Checklist Score From Baseline to Month 60

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-7.93
B - Placebo-8.02

Change in Independence Scale Score From Baseline to Month 60

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-26.30
B - Placebo-24.86

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-14.21
B - Placebo-14.51

Change in Stroop Interference Test - Interference From Baseline to Month 60

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-7.57
B - Placebo-8.61

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-15.25
B - Placebo-19.13

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-10.95
B - Placebo-11.36

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-4.53
B - Placebo-4.76

Change in Total Motor Score From Baseline to Month 60

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day18.06
B - Placebo19.18

Change in Verbal Fluency Test From Baseline to Month 60

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-5.07
B - Placebo-4.47

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventionrank (Mean)
A - Coenzyme Q10 2400 mg/Day303.3
B - Placebo306.7

Number Completing Study at Assigned Dosage Level

(NCT00608881)
Timeframe: 5 years

Interventionparticipants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day98
B - Placebo108

Time to a Three-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day917
B - Placebo911

Time to a Two-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day553
B - Placebo549

Reviews

2 reviews available for eicosapentaenoic acid ethyl ester and Huntington Disease

ArticleYear
Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis.
    Acta neuropsychiatrica, 2019, Volume: 31, Issue:4

    Topics: Eicosapentaenoic Acid; Humans; Huntington Disease; Randomized Controlled Trials as Topic; Treatment

2019
Ethyl-EPA in Huntington disease: potentially relevant mechanism of action.
    Brain research bulletin, 2007, Apr-30, Volume: 72, Issue:2-3

    Topics: Animals; Brain; Clinical Trials as Topic; Eicosapentaenoic Acid; Humans; Huntington Disease

2007

Trials

4 trials available for eicosapentaenoic acid ethyl ester and Huntington Disease

ArticleYear
Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:10

    Topics: Adult; Aged; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Huntington Disease; Male; M

2015
Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
    Archives of neurology, 2008, Volume: 65, Issue:12

    Topics: Adult; Analysis of Variance; Canada; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up S

2008
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
    Neurology, 2005, Jul-26, Volume: 65, Issue:2

    Topics: Adult; Apoptosis; Brain; Cohort Studies; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans;

2005
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment.
    Neuroreport, 2002, Jan-21, Volume: 13, Issue:1

    Topics: Aged; Atrophy; Brain; Double-Blind Method; Dyskinesia, Drug-Induced; Eicosapentaenoic Acid; Female;

2002

Other Studies

2 other studies available for eicosapentaenoic acid ethyl ester and Huntington Disease

ArticleYear
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
    Neurobiology of aging, 2011, Volume: 32, Issue:12

    Topics: Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Eicosapentaenoic Acid; Huntington Disea

2011
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
    Experimental neurology, 2005, Volume: 196, Issue:2

    Topics: Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphopr

2005